Since 2010, the landscape of multiple sclerosis care has transformed to encompass a variety of medications, each having unique benefits, risks, and side effect profiles. Dr. Jonathan Howard discusses how to match treatment strength to disease severity and balance patient risk tolerance with evolving therapeutic options, from long-standing injectables to infusions and oral therapies. Dr. Howard is an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital in New York.

IL-5 is a key driver of Type 2 inflammation in patients with severe asthma, promoting downstream effects like mucus plugging and epithelial barrier dysfunction. Given these impacts, targeted therapy with biologics can play a role in severe asthma management. Join Drs. Diego Maselli, Anju Peters, and Monica Kraft as they explore the impacts of IL-5 and share perspectives on patient selection and shared decision-making for targeted therapies. Dr. Maselli is a Professor of Medicine at the Long School of Medicine at UT Health in San Antonio. Dr. Peters is a Professor of Medicine and Associate Chief of Clinical Research and Practice Innovation at Northwestern Medicine in Chicago. Dr. Kraft is a System Chair of the Samuel Bronfman Department of Medicine and a Professor of Medicine at the Icahn School of Medicine at Mount Sinai Health Systems in New York.

This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.

The landscape of medication management for patients with pulmonary hypertension (PH) has significantly changed with the introduction of combination therapy and recent trial data. This activity presents the latest evidence and breaks down new approaches to the management of PH. Join our experts to find out how your daily practice will be affected.

Chronic kidney disease-associated pruritus (CKD-aP) is an underreported and underdiagnosed condition that affects a significant proportion of patients with advanced kidney disease undergoing dialysis. But with the approval of difelikefalin, many patients have experienced symptom improvement not only in their itching but in their quality of life. Join the experts as they review the newest real-world data and clinical results of difelikefalin presented at ERA.

This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions and the 92nd European Atherosclerosis Society (EAS) Congress. From clinical trials like PIONEER-AF, VOYAGER PAD, SHASTA 2 and MUIR to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.

With so many potential therapies emerging for sickle cell disease, where are we with the treatment of adults and children? Dr. Charles Turck joins Dr. Clifford Takemoto, the Chief of the Clinical Division of Hematology at St. Jude Children’s Research Hospital in Memphis, Tennessee, to share therapeutic updates from the 64th Annual American Society of Hematology Meeting.

Underrepresentation is widespread in hematological clinical trials. To learn more about the challenges preventing representation—and possible solutions—Dr. Charles Turck joins Dr. Namrata Chandhok from the Sylvester Comprehensive Cancer Center at the University of Miami to share insights on inclusion in clinical trials from the American Society of Hematology annual Meeting.

Collaborative care is fundamental for critically ill patients, especially when it comes to medication dosing. To explore key considerations on dosing and share insights from their presentations at IDWeek 2022, Dr. Charles Turck is joined by Dr. Adhi Fatima from the Baylor College of Medicine and Mei Chang from the Montefiore Medical Center at the Weiler Division Einstein Campus.

The monkeypox outbreak has taken the nation by storm, leading to an increase in diagnostic and vaccination resources. But has this virus prepared us for future infectious disease outbreaks? Joining Dr. Charles Turck to share lessons we’ve learned from the monkeypox outbreak is Dr. Jason Zucker from the Columbia University Irving Medical Center.

Results from the TROPiCS-02 trial may impact survival for patients with receptor–positive/HER2-negative breast cancer. To find out why, Dr. Hope Rugo from the University of California San Francisco Comprehensive Cancer Center joins Dr. Pavani Chalasani to talk about the study and how it might impact the future of breast cancer treatment.